MARKET

RNA

RNA

Avidity Biosciences, Inc.
NASDAQ
31.12
-1.41
-4.33%
After Hours: 31.00 -0.12 -0.39% 18:57 02/21 EST
OPEN
32.72
PREV CLOSE
32.53
HIGH
33.21
LOW
31.06
VOLUME
1.43M
TURNOVER
--
52 WEEK HIGH
56.00
52 WEEK LOW
13.68
MARKET CAP
3.71B
P/E (TTM)
-10.7396
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RNA last week (0210-0214)?
Weekly Report · 5d ago
Avidity Biosciences: Undervalued Entry Point with Promising 2025 Pipeline Despite Market Challenges
TipRanks · 5d ago
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q4 2024 Commentary
Seeking Alpha · 02/14 01:58
Janus Henderson Global Life Sciences Fund Q4 2024 Commentary
Seeking Alpha · 02/13 01:40
Weekly Report: what happened at RNA last week (0203-0207)?
Weekly Report · 02/10 10:40
Chardan unveils four top biotech picks for 2025
TipRanks · 02/06 13:00
Weekly Report: what happened at RNA last week (0127-0131)?
Weekly Report · 02/03 10:44
Weekly Report: what happened at RNA last week (0120-0124)?
Weekly Report · 01/27 10:46
More
About RNA
More
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.
Recently
Symbol
Price
%Change

Webull offers Avidity Biosciences Inc stock information, including NASDAQ: RNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNA stock methods without spending real money on the virtual paper trading platform.